A.R.T. Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

A.R.T. Advisors’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-45,823	Closed	-$1.03M	–	1777
2019 Q1	$1.03M	Buy	45,823 +23,125	+102%	+$497K	0.06%	473
2018 Q4	$413K	Buy	+22,698	New	+$356K	0.03%	802
2018 Q2	–	Sell	-68,294	Closed	-$362K	–	1919
2018 Q1	$362K	Buy	68,294 +28,724	+73%	+$205K	0.01%	1073
2017 Q4	$336K	Buy	+39,570	New	+$487K	0.01%	1027
2017 Q3	–	Sell	-10,070	Closed	-$188K	–	1834
2017 Q2	$188K	Buy	+10,070	New	+$227K	0.01%	1175

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

A.R.T. Advisors's RARX Position: Q2 2019 in Review

A.R.T. Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2019, closing a stake of 45,823 shares — an estimated $1.03M sold.

A.R.T. Advisors first reported a position in RARX in Q2 2017 and held it in 5 quarters. The position peaked at $1.03M in Q1 2019. 118 funds tracked by Wall St. Rank hold RARX as of Q2 2019.

A.R.T. Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
A.R.T. Advisors sold 45,823 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $1.03M.
A.R.T. Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 5 quarters.
A.R.T. Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $1.03M in Q1 2019.
118 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.